Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Polyphor Proceeding With POL7080 Testing After Roche Hands Antibiotic Back

This article was originally published in Scrip

Executive Summary

Polyphor Ltd says it will proceed alone with Phase II testing of its macrocycle antibiotic candidate POL7080 after Roche Holdings AG decided it would take too long to develop the investigational drug for treating patients with severe Pseudomonas aeruginosa infections, and so handed it back to the Swiss biotech.

You may also be interested in...

Summit Completes 2017 With Discuva Buy

After good news on the funding front in the 2017 third quarter, UK biotech Summit Therapeutics has completed the year on a high, acquiring fellow UK biotech Discuva to add a novel antibiotic discovery platform to its expertise.

Roche Goes Back To Nature With Warp Drive Antibiotic Pact

The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'

BMS's Zeposia Shines in Ulcerative Colitis Phase III Study

BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts